Abstract:Background: The transmembrane subunit of the HIV envelope protein, gp41 is a vulnerable target to inhibit HIV entry. There is one fusion inhibitor T20 (brand name: Fuzeon, generic name: enfuvirtide) available by prescription. However, it has several drawbacks such as a high level of development of drug resistance, a short-half life in vivo, rapid renal clearance, low oral bioavailability, and it is only used as a salvage therapy. Therefore, investigators have been studying a variety of different modalities to attempt to overcome these limitations. Methods: Comprehensive literature searches were performed on HIV gp41, inhibition mechanisms, and inhibitors. The latest structural information was collected, and multiple inhibition strategies targeting gp41 were reviewed. Results: Many of the recent advances in inhibitors were peptide-based. Several creative modification strategies have also been performed to improve inhibitory efficacy of peptides and to overcome the drawbacks of T20 treatment. Small compounds have also been an area of intense research. There is a wide variety in development from those identified by virtual screens targeting specific regions of the protein to natural products. Finally, broadly neutralizing antibodies have also been important area of research. The inaccessible nature of the target regions for antibodies is a challenge, however, extensive efforts to develop better neutralizing antibodies are ongoing. Conclusion: The fusogenic protein, gp41 has been extensively studied as a promising target to inhibit membrane fusion between the virus and target cells. At the same time, it is a challenging target because the vulnerable conformations of the protein are exposed only transiently. However, advances in biochemical, biophysical, structural, and immunological studies are coming together to move the field closer to an understanding of gp41 structure and function that will lead to the development of novel drugs and vaccines.

Design of a protein surface antagonist based on alpha-helix mimicry: inhibition of gp41 assembly and viral fusion.

Design of a Protein Surface Antagonist Based on α-Helix Mimicry: Inhibition of gp41 Assembly and Viral Fusion We thank the National Institutes of Health for support of this work and the Deutsche Forschungsgemeinschaft (DFG) for a research fellowship to O.K.

Design, Synthesis and Activity Evaluation of Novel Peptide Fusion Inhibitors Targeting HIV-1 Gp41

Short Communication: in VitroSynergy Between Peptides or Neutralizing Antibodies Targeting the N- and C-Terminal Heptad Repeats of HIV Type 1 Gp41

Identification Of A Critical Motif For The Human Immunodeficiency Virus Type 1 (Hiv-1) Gp41 Core Structure: Implications For Designing Novel Anti-Hiv Fusion Inhibitors

Helical Interactions in the HIV-1 Gp41 Core Reveal Structural Basis for the Inhibitory Activity of Gp41 Peptides.

Design of artificial α-helical peptides targeting both gp41 deep pocket and subpocket as potent HIV-1 fusion inhibitors

Correction: HIV-1 Fusion is Blocked Through Binding of GB Virus C E2D Peptides to the HIV-1 Gp41 Disulfide Loop.

HIV Entry Inhibitors Targeting Gp41: from Polypeptides to Small-Molecule Compounds

Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide.

Inhibition of human immunodeficiency virus type 1 infectivity by the gp41 core: role of a conserved hydrophobic cavity in membrane fusion.

The Mechanism by Which Molecules Containing the HIV Gp41 Core-Binding Motif HXXNPF Inhibit HIV-1 Envelope Glycoprotein-Mediated Syncytium Formation.

Design and Biological Evaluation of M-Xylene Thioether-Stapled Short Helical Peptides Targeting the HIV-1 Gp41 Hexameric Coiled-Coil Fusion Complex.

Inhibition of HIV-1 infection by a fusion domain binding peptide from the HIV-1 envelope glycoprotein GP41.

HIV-1 Gp41 Fusion Intermediate: a Target for HIV Therapeutics.

De Novo Design of Isopeptide Bond-Tethered Triple-Stranded Coiled Coils with Exceptional Resistance to Unfolding and Proteolysis: Implication for Developing Antiviral Therapeutics

Computational Study of Hiv-1 Gp41 Nhr Trimer: Inhibition Mechanisms of N-Substituted Pyrrole Derivatives and Fragment-Based Virtual Screening

Inhibition of HIV Entry by Targeting the Envelope Transmembrane Subunit gp41

An Effective Strategy for Recapitulating N-terminal Heptad Repeat Trimers in Enveloped Virus Surface Glycoproteins for Therapeutic Applications.

Determination of the HIV-1 gp41 fusogenic core conformation modeled by synthetic peptides: applicable for identification of HIV-1 fusion inhibitors.

Design of highly potent HIV fusion inhibitors based on artificial peptide sequences.